FIR Against Aurobindo Pharma Official, Others for Alleged Rs 3,600 Crore Share Acquisition Scam
FIR
Advertisement
Vijayawada: The non-executive director of Aurobindo Pharma, Penaka Sarathchandra Reddy has come under scrutiny by the Crime Investigation Department (CID) of Andhra Pradesh along with several prominent figures for alleged forced acquisition of shares in Kakinada Seaports Limited (KSPL) and Kakinada SEZ, valued at Rs 3,600 crore, during the tenure of the previous YSRCP government.
The CID has issued a lookout circular (LOC) for Penaka along with YSRCP MP Vijayasai Reddy, and Vikrant Reddy, the son of MP Y.V. Subba Reddy, preventing the individuals from leaving the country as part of an ongoing investigation into a case filed under various sections of the Indian Penal Code, including extortion, cheating, forgery, and other offences.
No Relation to Kakinada Seaports and Kakinada SEZ: Aurobindo Pharma Issues Clarification
Meanwhile, Aurobindo Pharma has issued a statement and denied any association with the entities.
"Aurobindo Pharma Limited, or its subsidiaries, are in no way connected with the ownership or operations of Kakinada Seaports Limited and Kakinada Special Economic Zone (SEZ) Limited, including Auro Infra Private Limited," the drugmaker said in a statement.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.